Transaction #22015 · Form 4 · 0001780660-25-000002
Adaptive Biotechnologies Corp · Exercise / conversion · Common Stock
Adaptive Biotechnologies Corp · Transacted December 15, 2025 · Filed December 17, 2025
What does this filing report?
An SEC Form 4 filing for Adaptive Biotechnologies Corp records an exercise / conversion involving Common Stock on December 15, 2025. The reported quantity was 39,849. The filing date is December 17, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company CIK
- 0001478320
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 39,849
- Reported price
- 3.99
- Reference value
- 158,997.51
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 429,868
- Ownership description
- Not reported
- SEC acceptance time
- Dec 17, 2025, 7:06 PM EST
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- LO FRANCIS ↗
Chief People Officer
CIK 0001780660
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
- F2
- The price reported for this transaction is a weighted -average price. The shares were sold in multiple transactions ranging from $15.37 to $16.03, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3
- The option is fully vested and exercisable.
- F4
- The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- F5
- The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.